OOIR: Observatory of International Research

Papers

(The TQCC of Xenobiotica is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Expression of cytochrome P450 isozyme transcripts and activities in human livers	29
Effect of rutin on pharmacokinetic modulation of diclofenac in rats	21
Metabolism study of hesperetin and hesperidin in rats by UHPLC-LTQ-Orbitrap MSⁿ	21
Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens	21
Metabolism and in vitro drug–drug interaction assessment of viloxazine	17
Amalgamation of in-silico, in-vitro and in-vivo approach to establish glabridin as a potential CYP2E1 inhibitor	16
Comparison between lab variability andin silicoprediction errors for the unbound fraction of drugs in human plasma	15
In silico prediction of volume of distribution of drugs in man using conformal prediction performs on par with animal data-based models	13
FXR activation prevents liver injury induced byTripterygium wilfordiipreparations	13
Predictability of human pharmacokinetics of drugs that undergo hepatic organic anion transporting polypeptide (OATP)-mediated transport using single-species allometric scaling in chimeric mice with hu	12
Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats	12
Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes	12
Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer–Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active m	11
Effects of paeoniflorin on the activities and mRNA expression of rat CYP1A2, CYP2C11 and CYP3A1 enzymes in vivo	11
Differential interactions of carbamate pesticides with drug transporters	11
Pharmacokinetics, tissue distribution and excretion of five rhubarb anthraquinones in rats after oral administration of effective fraction of anthraquinones from rheum officinale	11
Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human	10
Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation	10
Molecular mechanisms of ethanol biotransformation: enzymes of oxidative and nonoxidative metabolic pathways in human	9
Bidirectional regulation of genistein on the proliferation and differentiation of C2C12 myoblasts	9
Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor	9
Newly identified tree shrew cytochrome P450 2B6 (CYP2B6) and pig CYP2B6b are functional drug-metabolising enzymes	9
In vivo pharmacokinetics, distribution, and excretion of an anticancer agent isolated from red ginseng, in rat	8
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole	8
Metal-metal interaction and metal toxicity: a comparison between mammalian and D. melanogaster	8

Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS	8
Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid	8
Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds	7
The permeability characteristics and interaction of main components from Si-Ni-San in a MDCK epithelial cell monolayer model	7
Roles of cytochrome P450 2A6 in the oxidation of flavone, 4′-hydroxyflavone, and 4′-, 3′-, and 2′-methoxyflavones by human liver microsomes	7
Oral antibiotics used in the treatment of chronic rhinosinusitis have limited penetration into the sinonasal mucosa: a randomized trial	7
Curcumin-loaded hydroxypropyl-β-cyclodextrin inclusion complex with enhanced dissolution and oral bioavailability for epilepsy treatment	7
Evaluation of the drug–drug interaction potential for trazpiroben (TAK-906), a D₂/D₃ receptor antagonist for gastroparesis, towards cytochrome P450s and transporters	7
A comprehensive profiling and identification of liquiritin metabolites in rats using ultra-high-performance liquid chromatography coupled with linear ion trap–orbitrap mass spectrometer	7
LncRNA HOTAIR modulates the expression of OATP1B1 in HepG2 cells by sponging miR-206/miR-613	7
Absorption, distribution, metabolism, and excretion of three [¹⁴C]PBDE congeners in laying hens and transfer to eggs.	6
Metabolism, excretion, and pharmacokinetics of [¹⁴C]mirogabalin, a novel α₂δ ligand, in healthy volunteers following oral administration	6
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor	6
Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment	6
Metabolic activation of deferiprone mediated by CYP2A6	6
In vitro study of the drug–drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers	6
Metabolic exhaustion and casein kinase 1α drive deguelin-induced premature red blood cell death	6
Metabolism of bifenthrin, β-cyfluthrin, λ-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes	6
A comprehensive analysis of six forms of cytochrome P450 2C (CYP2C) in pigs	6
Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin A in allogeneic haematopoietic stem cell transplantation recipients	6
Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients’ characteristics: a review of the literature and simulations	6
Comparative assessment for rat strain differences in metabolic profiles of 14 drugs in Wistar Han and Sprague Dawley hepatocytes	6
Molecular docking and oxidation kinetics of 3-phenyl coumarin derivatives by human CYP2A13	6
Metabolic activation of zolmitriptan mediated by CYP2D6	6
Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans	6
Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559	6
Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy	6
Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models	6
In silico predictions of the human pharmacokinetics/toxicokinetics of 65 chemicals from various classes using conformal prediction methodology	5
MicroRNA-mediated calcineurin signaling activation induces CCL2, CCL3, CCL5, IL8, and chemotactic activities in 4,4′-methylene diphenyl diisocyanate exposed macrophages	5
Effect of naringenin on the pharmacokinetics of metoprolol succinate in rats	5
Inhibitory effect of ketoconazole, quinidine and 1-aminobenzotriazole on pharmacokinetics of l-tetrahydropalmatine and its metabolite in rats	5
Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects	5
Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans	5
Meeting report: 3rd workshop of the peptide ADME discussion group	5
Polymorphisms in xenobiotic metabolism-related genes in patients with hepatocellular carcinoma: a case–control study	5
MRP4 is responsible for the efflux transport of mycophenolic acid β-d glucuronide (MPAG) from hepatocytes to blood	5
Metabolic map of the antiviral drug podophyllotoxin provides insights into hepatotoxicity	5
Absorption, metabolism, and excretion of [¹⁴C]YY-20394, a highly selective PI3K-Delta inhibitor in humans	5
Evaluation of covalent binding of flutamide and its risk assessment using ¹⁹F-NMR	5
Comprehensive characterization and optimization of Caco-2 cells enabled the development of a miniaturized 96-well permeability assay	5
Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma	5
Evaluation of species differences in the metabolism of the selective Na_V1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase	5
Hepatotoxic effect of tramadol and O-desmethyltramadol in HepG2 cells and potential role of PI3K/AKT/mTOR	4
UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers	4
Pomegranate peel polyphenols interaction with intestinal flora and its metabolic transformation	4
In vitro drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymes	4
Prediction of pharmacokinetic clearance and potential Drug-Drug interactions for omeprazole in the horse using in vitro systems	4
Absorption, distribution, metabolism, and excretion of [¹⁴C]TPN729 after oral administration to rats	4
Comparative toxicokinetics of bisphenol S and bisphenol AF in male rats and mice following repeated exposure via feed	4

Inhibition of CYP3A4 and CYP3A5 expression by scutellarin is not mediated via the regulation of hsa-miR-27a, 27b, 148a, 298 and 451a levels	4
First dose in neonates: pharmacokinetic bridging study from juvenile mice to neonates for drugs metabolized by CYP3A	4
Characterisation of intravenous pharmacokinetics in Göttingen minipig and clearance prediction using established in vitro to in vivo extrapolation methodologies	4
Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes	4
Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic	4
Pharmacokinetics, tissue distribution, plasma protein binding rate and excretion of sinoacutine following intravenous administration in female and male Sprague-Dawley rats	4
Evaluation of molecular markers GSTM1 and GSTT1 and clinical factors in breast cancer: case-control study and literature review	4
In vitro effects of peimine on the activity of cytochrome P450 enzymes	4
Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized TK-NOG mouse	4
Metabolites identification and species comparison of Oroxylin A, an anti-cancer flavonoid, in vitro and in vivo by HPLC-Q-TOF-MS/MS	4
In vitro modulatory effects of ginsenoside compound K, 20(S)-protopanaxadiol and 20(S)-protopanaxatriol on uridine 5′-diphospho-glucuronosyltransferase activity and expression	4
Plasma protein binding, metabolism, reaction phenotyping and toxicokinetic studies of fenarimol after oral and intravenous administration in rats	4
Quantitative prediction of OATP1B-mediated drug–drug interactions using endogenous biomarker coproporphyrin I	4
Liquid chromatography-tandem mass spectrometry analysis of oxidation of 2′-, 3′-, 4′- and 6-hydroxyflavanones by human cytochrome P450 enzymes	4
Numerical analysis of time-dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting	4
Population pharmacokinetics of mycophenolic acid in pediatric patients with juvenile dermatomyositis and optimization of limited sampling strategy	4
Sex differences in the pharmacokinetics and tissue residues of Macleaya cordata extracts in rats	4
Differential changes in the pharmacokinetics of doxorubicin in diethylnitrosamine-induced hepatocarcinoma model rats	4
Plasma and hepatic concentrations of acetaminophen and its primary conjugates after oral administrations determined in experimental animals and humans and extrapolated by pharmacokinetic modeling	4
Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase	4
Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS:in vivostudy of rat plasma, urine, bile, and faeces	4
Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters	4
Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children	4
4-O-galloylalbiflorin inhibits the activity of CYP3A, 2C9, and 2D in human liver microsomes	4
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)	4
Identification of the metabolites produced following Iris tectorum Maxim oral administration and a network pharmacology-based analysis of their potential pharmacological properties	4